SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy to market Daiichi Sankyo’s innovative products in Malaysia

21 Dec 2011 Evaluate

Daiichi Sankyo Company and Ranbaxy laboratories have entered into strategic alliance for synergistic initiative in Malaysia where Ranbaxy will market innovative products originally discovered by Daiichi Sankyo. Following Singapore, this is the company’s second marketing synergy in the ASEAN region.

Ranbaxy will market Cravit (levofloxacin), the synthetic antibacterial agent originally discovered by Daiichi Sankyo, in Malaysia from January 1, 2012. The product is currently commercialized by First Pharmaceutical in Malaysia.

Daiichi Sankyo and First Pharmaceutical have agreed to transfer the marketing rights of Cravit (levofloxacin) from First Pharma to Ranbaxy. First Pharma will continue to be Daiichi Sankyo’s marketing partner for other products (except Cravit) it had in-licensed from Daiichi Sankyo.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×